Use of compounds that stimulate cgmp
AssigneeBayer HealthCare LLC
InventorsHelmut Haning, Erwin Bischoff, UIrich Niewohner, Maria Niewohner
Life of this patent
Estimating the term…
Abstract
The invention relates to the use of compounds that stimulate cGMP, in particular imidazo[1,3,5]triazinones, for producing a medicament for the treatment and/or prophylaxis of diseases, in which the clinical picture can be improved and/or cured by the improvement of the micro-circulation of tissue containing a phosphodiesterase that metabolises cGMP.
Claims10
A method for the treatment and/or prophylaxis of diseases in which an improvement in and/or a cure of a syndrome can be achieved by improving the microcirculation of a tissue which contains a cGMP-metabolizing phosphodiesterase comprising administering to a subject an effective amount of a cGMP-stimulating compound.
A pharmaceutical for the treatment and/or prophylaxis of diseases in which an improvement in and/or a cure of a syndrome can be achieved by improving the microcirculation of a tissue which contains a cGMP-metabolizing phosphodiesterase, which pharmaceutical comprises at least one cGMP-stimulating compound.
A pharmaceutical for the treatment and/or prophylaxis of coronary heart disease, cardiac insufficiency, pulmonary hypertension, bladder diseases, prostate hyperplasia, nitrate-induced tolerance or diseases of the eye, central retinal or posterior cilliary arterial occlusion, central retinal venous occlusion, optical neuropathy, macular degeneration, diabetes, disturbances of the peristalsis of the stomach and esophagus, female infertility, premature labor, preeclampsia, alopecia, psoriasis, renal syndrome, cystic fibrosis and/or cancer, which pharmaceutical comprises at least one cGMP-stimulating compound.
A pharmaceutical for improving perception, concentration performance, learning performance and/or memory performance, for improving perception, concentration performance, learning performance and/or memory performance following cognitive disturbances, age-associated learning and memory disturbances, age-associated memory loss, vascular dementia, craniocerebral trauma, stroke, dementia which occurs after strokes (post-stroke dementia), post-traumatic craniocerebral trauma, general disturbances of concentration, concentration disturbances in children suffering from learning and memory problems, vascular dementia, dementia associated with Lewy bodies, dementia associated with degeneration of the frontal lobes including Pick's syndrome, Parkinson's disease, progressive nuclear palsy, dementia associated with corticobasal degeneration, amyolateralsclerosis (ALS), Huntington's disease, multiple sclerosis, thalamic degeneration, Creutzfeld-Jacob dementia, new variant Creutzfeld-Jacob dementia, HIV dementia, schizophrenia associated with dementia or Korsakoff's psychosis, which pharmaceutical comprises at least one cGMP-stimulating compound.
A pharmaceutical which comprises at least one compound imidazo[1,3,5]triazinone of the general formula (I)
- in which
- R1 is straight-chain or branched alkyl having up to 4 carbon atoms,
- R2 is straight-chain or branched alkyl having up to 4 carbon atoms or is (C1-C8)-cycloalkyl,
- R3 is hydrogen or straight-chain or branched alkyl having up to 4 carbon atoms,
- R4 and R5 are identical or different and are hydrogen. (C1-C6)-alkoxy or hydroxyl or are (C1-C8)-alkyl which is optionally substituted, up to 3 times, identically or differently, by hydroxyl, (C1-C6)-alkoxy or radicals of the formulae
- in which
- R6 and R7 are identical or different and are hydrogen or (C1-C6)-alkyl,
- and/or for its part, (C1-C8)-alkyl is optionally substituted by phenyl or phenoxy which, for their part, are optionally substituted, once to three times, identically or differently, by halogen, hydroxyl, (C1-C6)-alkoxy, (C1-C6)-alkyl or a radical of the formula —SO2NR8R9,
- in which
- R8 and R9 are identical or different and are hydrogen or (C1-C6)-alkyl,
- or
- R4 is hydrogen or methyl
- and
- R5 is radicals of the formulae
- or
- is phenyl which is optionally substituted, up to 3 times, identically or differently, by halogen, acetyl, (C1-6)-alkoxy or radicals of the formulae
- in which
- R10 and R11 are identical or different and are hydrogen or (C 1-C4)-alkyl
- R12 and R13 are identical or different and are hydrogen or (C1-C6)-alkyl,
- or
- R4 and R5, together with the nitrogen atom to which they are bonded, are radicals of the formulae
- in which
- R14 and R15 are identical or different and are hydroxyl, hydrogen or (C1-C4-alkyl which is optionally substituted by hydroxyl,
- or
- R14 is hydrogen
- and
- R15 is a radical of the formula
- or
- R14 and R15 together form a radical of the formula ═N—O—CH3,
- R16 is hydrogen or (C1-C5)-alkyl which is optionally substituted by hydroxyl, or
- is a 5- to 6-membered aromatic heterocycle having up to 3 hetero atoms from the series, S, N and/or O,
- and the salts, hydrates, hydrates of the salts, N-oxides and isomeric forms thereof.
Dependencies are inferred from the claim text.